3D Brain Marker Predicts Hydrocephalus Surgery Success

A new three-dimensional brain imaging marker shows promise in predicting which patients with normal pressure hydrocephalus (NPH) will benefit most from shunt surgery, according to research published in the Journal of Neurosurgery. The marker, derived from advanced MRI analysis, could help clinicians better identify individuals likely to experience improved cognition and gait following surgical intervention, addressing a longstanding challenge in managing this treatable form of dementia.

Normal pressure hydrocephalus, often mistaken for Alzheimer’s or Parkinson’s disease, involves an abnormal buildup of cerebrospinal fluid in the brain’s ventricles. While shunt surgery — which drains excess fluid — can significantly improve symptoms in some patients, up to 40 percent experience little to no benefit, making patient selection critical. Currently, diagnosis relies on clinical symptoms, neuropsychological testing, and invasive cerebrospinal fluid tap tests, which are not always definitive.

The study, led by researchers at Kyoto University Graduate School of Medicine in Japan, analyzed preoperative 3D T1-weighted MRI scans from 62 patients diagnosed with idiopathic NPH who subsequently underwent ventriculoperitoneal shunt placement. Using voxel-based morphometry and surface-based analysis, the team identified a specific pattern of cortical thinning in the frontal and parietal lobes that strongly correlated with postoperative improvement in gait speed and cognitive function six months after surgery.

Patients exhibiting this distinct 3D brain atrophy pattern were 3.8 times more likely to achieve a meaningful clinical response — defined as a improvement in both the Japanese version of the Gravity Scale for Hydrocephalus (J-GSH) and the Mini-Mental State Examination (MMSE) — compared to those without the pattern. The marker demonstrated a sensitivity of 76 percent and specificity of 82 percent in predicting surgical success.

“We’ve long struggled to predict who will truly benefit from shunt surgery,” said Dr. Aiko Tanaka, lead author of the study and neurologist at Kyoto University Hospital. “This 3D cortical signature offers an objective, noninvasive way to supplement clinical judgment. It doesn’t replace existing assessments, but it adds a layer of precision that could reduce unnecessary surgeries and focus resources on those most likely to improve.”

The researchers emphasized that the marker reflects neurodegenerative changes associated with chronic ventricular enlargement rather than causative pathology. In other words, the observed cortical thinning is likely a consequence of long-term fluid pressure on brain tissue, not the direct cause of hydrocephalus symptoms. This distinction is important, as it suggests the marker identifies brains that have undergone measurable structural adaptation — and thus may retain sufficient plasticity to respond to pressure normalization.

External experts cautioned that while the findings are promising, the study was retrospective and conducted at a single center. Dr. Michael Williams, professor of neurosurgery at the University of California, San Francisco, who was not involved in the research, noted that prospective validation across diverse populations is essential before clinical adoption. “We need to see if this pattern holds up in larger, multicenter studies and whether it works alongside other biomarkers like amyloid PET or tau imaging to differentiate NPH from comorbid neurodegenerative diseases,” he said.

The research team acknowledged limitations, including the relatively small sample size and the absence of long-term follow-up beyond six months. They are now designing a prospective trial to test the marker’s utility in real-time surgical decision-making, with plans to incorporate machine learning models to refine its predictive accuracy across different MRI protocols and scanner types.

If validated, the 3D brain marker could become part of a multimodal diagnostic approach for NPH, joining clinical evaluation, neuropsychological testing, and cerebrospinal fluid biomarkers. For patients and families facing difficult decisions about invasive surgery, such tools may offer clearer insight into potential outcomes, helping balance hope with realistic expectations in the management of this complex condition.